相关实验视频
Updated: Jul 20, 2026

05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
国际刑警组织_MI - 一个研究平台概念,用于IT支持的药物治疗安全研究
Daniel Neumann1, Sebastian Staeubert1, Alexander Struebing1
1Institute of Medical Informatics, Statistics and Epidemiology; University Leipzig; Leipzig; Germany.
Studies in health technology and informatics
|May 17, 2025
概括
国际刑警组织平台将现实数据集成到德国医院,通过IT支持的工作流程和临床决策支持系统,提高药物治疗安全性和减少药物错误.
科学领域:
- 医疗信息学 医疗信息学
- 药物监督 药物监督 药物监督
- 医疗保健服务研究 医疗服务研究
背景情况:
- 药剂师的干预对于减少药物错误和药物治疗安全至关重要.
- 信息技术 (IT) 支持的工作流程,包括临床决策支持系统 (CDSS),增强实时临床决策.
- 德国联邦医院系统在将研究纳入常规护理方面面临着独特的挑战.
研究的目的:
- 引入INTERPOLAR研究平台,旨在将现实数据集成到德国联邦医院系统内的常规护理工作流程中.
- 利用基于FHIR的数据,预定义的触发器和实时反的CDS工具链来加强药物治疗安全研究.
- 通过过程映射和要求工程来支持多样化的研究设计,并将技术能力与临床工作流程保持一致.
主要方法:
- 在医疗信息化倡议 (MII) 下开发INTERPOLAR平台.
- 使用CDS工具链与基于FHIR的数据项和预定义的触发器.
- 实施一个集中式的健康数据仓库,确保大规模分析的GDPR合规.
- 流程映射和需求工程,以使技术解决方案与临床工作流程保持一致.
主要成果:
- 证明了文档的协调和改善了与毒品有关的问题 (DRP) 的检测.
- 通过数据集成和分析的自动化实现了效率提升.
- 促进了正在进行的关于药物坚持,不良药物事件 (ADEs) 和药剂师干预影响的研究.
结论:
- 国际刑警组织平台为药物治疗安全研究提供了一个可扩展的,联合的解决方案,通过将IT支持的工作流程嵌入常规护理中.
- 该平台推进基于证据的医学,并为全球药监工作做出贡献.
- 成功整合现实世界的数据可以提高药物相关问题的检测和管理.
相关概念视频
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

